Yeztugo $1B Q2 is NOT a $4B run-rate—the bull extrapolates a hot quarter into perpetuity. Realistic H2 2026 is $1.1–1.2B, not $2B sequential doubling.

• $1B quarterly figure annualized to $4B requires sequential doubling every quarter
• Realistic H2 2026 projection: $1.1–1.2B
• Pharma launches decelerate as penetration gets harder and early adopters exhaust

↩ rebuts: “Bull's $4B annualized run-rate claim”

Yeztugo operates in a contested category with ViiV's Apretude and Merck's pipeline—bull assumes zero share loss, which is wishful thinking.

• ViiV Healthcare (Pfizer/GSK/Shionogi) has Apretude (cabotegravir LA)
• Merck has own HIV pipeline

↩ rebuts: “Bull's blockbuster launch trajectory assumption”

AIDS Healthcare Foundation criticism is a fat-tail policy event that could erode pricing power in 40% of the global HIV market, not ESG noise.

• AHF publicly alleges Gilead 'benefits from taxpayer-funded research while limiting affordable treatment in LMICs'
• AHF has track record of pushing compulsory licensing campaigns and aggressive access lawsuits
• 40% of global HIV market is LMICs

↩ rebuts: “Bull's dismissal of AHF criticism as ESG noise”

Yeztugo may be replacement revenue for Biktarvy's patent cliff, not additive—if lenacapavir offsets only 30% of Biktarvy erosion, the franchise shrinks.

• Biktarvy is a $10B+ HIV backbone facing patent cliff into late 2020s
• Bull treats Yeztugo as additive revenue; math is very different if replacement

↩ rebuts: “Bull's additive revenue framing”

GAAP losses are NOT non-recurring accounting noise—$2.77B in special charges over six consecutive quarters is a pattern, not an event.

• Q1 2026: $1.0B special income charges
• Q2 2026: $679M special income charges
• Q2 2025: $251M
• Q3 2025: $253M
• Q4 2025: $400M write-off
• Q3 2025: $190M impairment
• Total: $2.77B over six quarters
• ~$460M per quarter of 'non-recurring' items

↩ rebuts: “Bull's dismissal of $10.5B GAAP net loss as non-cash, non-recurring”

Management widened full-year loss guidance, which contradicts the 'non-recurring charges' narrative—if truly one-time, forecasting should be possible.

• Widened full-year loss guidance indicates more impairment risk in pipeline book

↩ rebuts: “Bull's claim that charges are non-recurring and see-through to Street”

Forward P/E of 13.5× is not a 'gift'—consensus estimates ($9.87) bake in the 'charges are noise' narrative. If GAAP losses persist, forward EPS gets cut and P/E re-rates to 16–17× on revised numbers.

• $9.87 forward EPS is consensus estimate
• Forward P/E 13.5× becomes 16–17× on revised EPS if charges persist

↩ rebuts: “Bull's 13.5× forward P/E as compelling valuation”

GILD is NOT cheap relative to growth—PEG ratio of 2.14 exceeds 2.0 threshold, tangible book value is negative at -$1.18B, TTM revenue growth is only ~4.3%, and FY26 revenue guide is 0.6% BELOW consensus.

• PEG Ratio: 2.14 (peers typically 1.0–1.5)
• Tangible Book Value: -$1.18B
• P/B: 14× is meaningless with negative tangible book
• Revenue Growth TTM: ~4.3% YoY (not 10% base business growth)
• Trailing P/E: NM (negative TTM EPS)
• FY26 Revenue Guide: $30.25B (0.6% BELOW consensus)

↩ rebuts: “Bull's comparison table showing GILD at 13.5× forward P/E vs peers at 15–18×”

FCF yield of 7.4% is weaker than it appears—$22B in total debt and $4B annual dividend mean excess cash is already spoken for.

• $22B total debt
• $4B annual dividend
• Excess cash servicing debt and dividend rather than compounding

↩ rebuts: “Bull's FCF yield argument”

Trodelvy combo failure is a platform signal, not a one-trial blip—if Trodelvy + Keytruda failed, it raises structural questions about the oncology mechanism of action.

• Trodelvy + Keytruda (gold-standard checkpoint inhibitor) combo failure
• TROPiCS-02 monotherapy data is contested
• Next readout is binary

↩ rebuts: “Bull's 'already in the price' claim”

Binary Trodelvy monotherapy outcome has negative expected value—modest 5–8% rally if data holds vs 15–20% re-rating if disappoints, breaking $128 lower Bollinger band.

• If Trodelvy mono data holds: 5–8% relief rally
• If Trodelvy mono data disappoints: 15–20% re-rating, breaking $128 lower Bollinger band

↩ rebuts: “Bull's asymmetric setup claim”

Failed combo trial signals M&A pipeline (CymaBay, ImmunoGen) produces expensive write-downs without proportionate clinical wins—next acquisition carries higher discount.

• CymaBay, ImmunoGen acquisitions producing write-downs
• Path to growth via M&A is harder

↩ rebuts: “Bull's M&A optionality argument”

Macro setup is a headwind—86% probability of NO Fed cuts means T-bills yield 4.2%+, making GILD's 2.5% dividend yield uncompetitive vs risk-free alternatives.

• 86% probability of NO Fed cuts in 2026
• T-bills yield 4.2%+
• GILD dividend yield: 2.5%
• Beta: 0.33

↩ rebuts: “Bull's macro supportive tailwind thesis”

With 8% recession probability and equities at records, money rotates OUT of defensives INTO cyclicals—defensive bid is latent, not active.

• 8% recession probability
• Money chasing cyclicals (energy, materials) on soft-landing thesis
• Healthcare and staples lagging
• Defensive bid only activates 'when something breaks'

↩ rebuts: “Bull's defensive ballast in wobbles argument”

GILD beta of 0.33 is a liability—portfolio managers can buy TLT or BND for 4%+ yield with zero idiosyncratic risk.

• TLT, BND yield 4%+ with zero idiosyncratic risk vs GILD's 2.5% dividend with single-stock risk

↩ rebuts: “Bull's low beta as a feature”

Stock is in confirmed downtrend—below both 50-day ($129.75) and 200-day ($131.83) averages, 50 SMA ($129.52) below 200 SMA ($130.87), MACD negative for 4 consecutive sessions.

• 50-day average: $129.75
• 200-day average: $131.83
• Current price: $133.21 (below both)
• 50 SMA: $129.52 (below 200 SMA $130.87)
• MACD negative for 4 consecutive sessions
• ATR rising +30% in two months

↩ rebuts: “Bull's higher low and golden cross formation claim”

Stock failed to tag upper Bollinger band at $135.78 (intraday high $134.09 = $1.69 short)—clean resistance rejection, not 'almost a breakout.'

• Upper Bollinger band: $135.78
• Intraday high: $134.09
• Distance from Bollinger: $1.69

↩ rebuts: “Bull's 'almost a breakout' framing”

Stock is closer to 52-week LOW ($108.46) than 52-week HIGH ($157.29)—IBD called a downtrend with headline 'Gilead Slumps As Long-Term Uncertainty Clouds Massive HIV Beat.'

• 52-week high: $157.29
• 52-week low: $108.46
• Current: $133.21 (lower half of range)
• IBD headline: 'Gilead Slumps As Long-Term Uncertainty Clouds Massive HIV Beat'

↩ rebuts: “Bull's chart showing bullish alignment”

Sentiment score of 5.1/10 is unreliable, not contrarian—StockTwits unavailable and Reddit empty, meaning the signal lacks retail data.

• Sentiment score: 5.1/10
• StockTwits unavailable
• Reddit empty
• Signal is unreliable, not contrarian

↩ rebuts: “Bull's 5.1 sentiment as contrarian buy signal”